A 16-Week Randomised, Placebo-Controlled, Double-Blind, Double-Dummy, Parallel-Group Study Comparing the Efficacy and Safety of Tiotropium Inhalation Solution Delivered by the Respimat Inhaler (2 Actuations of 2.5 Mcg Once Daily) With That of Salmeterol From the Hydrofluoroalkane Metered Dose Inhaler (2 Actuations of 25 Mcg Twice Daily) in Moderate Persistent Asthma Patients With the B16-Arg/Arg Genotype.

Trial Profile

A 16-Week Randomised, Placebo-Controlled, Double-Blind, Double-Dummy, Parallel-Group Study Comparing the Efficacy and Safety of Tiotropium Inhalation Solution Delivered by the Respimat Inhaler (2 Actuations of 2.5 Mcg Once Daily) With That of Salmeterol From the Hydrofluoroalkane Metered Dose Inhaler (2 Actuations of 25 Mcg Twice Daily) in Moderate Persistent Asthma Patients With the B16-Arg/Arg Genotype.

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Feb 2017

At a glance

  • Drugs Tiotropium bromide (Primary) ; Salmeterol
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 01 Sep 2016 Results of safety analysis from pooled data (n= 3474) of this (NCT00350207) and six other trials (NCT01316380, NCT01172808, NCT01172821, NCT00772538, NCT00776984, NCT01340209), published in the Respiratory Medicine Journal.
    • 01 Aug 2011 Results published in the Journal of Allergy and Clinical Immunology.
    • 01 Oct 2008 Actual end date (Sep 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top